DDrare: Database of Drug Development for Rare Diseases

278. 巨大リンパ管奇形（頚部顔面病変）
［臨床試験数：19，薬物数：23（DrugBank：7），標的遺伝子数：5，標的パスウェイ数：62］

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bleomycin; Device: MRI; Indocyanine green; L04AA10; OK432; Picibanil; Propranolol; RAPAMUNE; Rapamune; Rapamycin; Rapamycin dosage; SIROLIMUS; Selenium; Sildenafil; Sildenafil 20 mg tablets; Sirolimus; Sirolimus 0,1% crème; Sirolimus 1mg/mL; Sirolimus Oral Liquid Product 1mg/mL; Topical 0.1% Sirolimus; Topical Vehicle; VT30; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04409145 (ClinicalTrials.gov)	October 1, 2020	11/5/2020	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation	Drug: VT30	Venthera, Inc.	NULL	Recruiting	18 Years	60 Years	All	51	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04409145
(ClinicalTrials.gov)

October 1, 2020

11/5/2020

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations

Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation

Drug: VT30

Venthera, Inc.

NULL

Recruiting

18 Years

60 Years

All

Phase 1;Phase 2

United States